Source: Annual Congress 2010 - Exercise training and pulmonary rehabilitation
Disease area: Airway diseases

Abstract

Introduction: Radical therapy for lung cancer contributes to muscle weakness, functional impairment and fatigue. Aim: To assess in patients with lung cancer the effects of radical therapy and to investigate the effects of a post treatment resistance training on exercise capacity, muscle force and fatigue. Methods: Patients with lung cancer, candidate for radical therapy, < 80 years, without severe co-morbidity interfering with exercise training, were included. Patients were evaluated at intake, after radical therapy and after resistance training. The variables include pulmonary function tests, exercise tests, peripheral muscle force and fatigue. Participants underwent a resistance training program for 12 weeks, 1 hour 3 times a week . 25 patients had to be included in order to observe significant differences at p<0.05 level between baseline and after radical therapy (*), baseline and after training (°), and before and after the resistance training (+).
Results: 25 patients, stage (I-III), (age: 63 ± 11 years; FEV₁: 87 ± 19 % pred.) were included. 10 patients completed the study. Values are means with standard deviation.

	Intake	After radical therapy	After resistance training
BMI (kg/m2)	26 ± 6	25 ± 3	29 ± 7
FEV1 (%pred.)	87 ± 19	69 ± 19 *	62 ± 15 +
VC (%pred.)	102 ± 17	78 ± 22 *	73 ± 25 +
6MWD (%pred.)	77 ± 12	73 ± 10	82 ± 10°
QF (%pred.)	97 ± 40	62 ± 17*	80 ± 22 +
Max.Load (%pred.)	109 ± 44	59 ± 12 *	77 ± 15 +
Fact-F (points)	8 ± 4	12 ± 3 *	10 ± 4 +

Conclusion: Radical treatment of patients with lung cancer decreases exercise capacity, muscle force and increases fatigue. 12 weeks of resistance training leads to a significant improvement in exercise capacity, muscle force and fatigue.

Rating:

Share or cite this content

Citations should be made in the following way:
B. Salhi, C. Haenebalcke, M. Nguyen, S. Perez, J. van Meerbeeck, E. Derom (Bruges, Liege, Brussels, Belgium). Resistance training in radically treated lung cancer patients. Eur Respir J 2010; 36: Suppl. 54, 1941

Member's Comments

No comment yet.

Related content which might interest you: Improvements in lung cancer surgery Source: Annual Congress 2011 - Surgery for lung cancer: pre-operative evaluation and results Year: 2011 Second-line medical treatment for nonsmall cell lung cancer: what happens in reality Source: Annual Congress 2010 - Lung cancer progress after first-line therapy: which treatment makes sense and which does not? Year: 2010 Treatment strategy for patients with locally advanced and metastatic nonsmall-cell lung cancer Source: Annual Congress 2011 - PG10 Management of thoracic tumours in practice: a HERMES basic course Year: 2011 Home-based rehabilitation program for lung cancer patients Source: Annual Congress 2011 - Exercise training: new populations, new techniques Year: 2011 Second-line medical treatment for nonsmall cell lung cancer: what the studies say Source: Annual Congress 2010 - Lung cancer progress after first-line therapy: which treatment makes sense and which does not? Year: 2010 Weekly administration of gemcitabine in outpatient clinic for the patients with recurrent non-small cell lung cancer after pulmonary resection Source: Eur Respir J 2006; 28: Suppl. 50, 781s Year: 2006 C-erbB-3 expression in non small cell lung cancer (NSCLC) patients treated by erlotinib Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010 Effects and feasibility of different types of endurance training in patients with end stage lung disease before lung transplantation Source: Annual Congress 2011 - The best abstracts in rehabilitation and chronic care 2011 (sponsored by Nutricia Advanced Medical Nutrition) Year: 2011 Who should treat lung cancer patients and where should they be treated? Source: Annual Congress 2009 - Fitness for radical therapy in lung cancer patients Year: 2009 Survival in 138 patients with non small cell lung cancer (NSCLC) treated with platinum together with gemcitabine or vinorelbine by a multidisciplinary team. Comparison with the Big Lung Trial Source: Eur Respir J 2006; 28: Suppl. 50, 781s Year: 2006 Resistance to chemotherapy in lung cancer Source: International Congress 2015 – Resistance to therapy in lung cancer Year: 2015 Swedish Lung Cancer Radiation Study Group: The value of induction chemotherapy for radiotherapy response in patients with non-small cell lung cancer Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010 Breath biomarkers of lung cancer and other diseases Source: Annual Congress 2010 - Advances on breath monitoring of inflammatory airway disease Year: 2010 Pulmonary rehabilitation after radically treated lung cancer patients: a pilot study Source: Annual Congress 2008 - Pulmonary rehabilitation for non-COPD and severe COPD; field exercise testing Year: 2008 6-month follow-up in patients with advanced homogeneous emphysema treated with endobronchial lung sealant therapy Source: Annual Congress 2011 - Endoscopic lung volume reduction: hype or hope? Year: 2011 Lung cancer and COPD multidisciplinary teams: Exploring comparisons of patient perceptions Source: Annual Congress 2010 - Optimising the care and management of patients with COPD Year: 2010 Evaluation of outpatient infections in lung cancer patients treated with chemotherapy and/or radiotherapy Source: Annual Congress 2012 - Screening, diagnosis, staging and treatment strategies for lung cancer Year: 2012 Novel aspects in lung cancer pathology: how does it help for selecting chemotherapy? Source: Annual Congress 2010 - PG4 Core Curriculum Postgraduate Course: Pathology for the clinician Year: 2010 The proportion of EGFR+ NSCLC patients never treated with TKI – A single institution Croatian experience Source: International Congress 2016 – Clinical aspects of lung cancer Year: 2016